August 17, 2016
Pivotal Therapeutics Inc. is in default of CSE requirements. Effective at market close, Pivotal Therapeutics, currently the subject of a Cease Trade Order, will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules.
Date: Effective market close, August 17, 2016
If you have any questions or require further information, or to be removed from the mailing list please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com